We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 287

The Supreme Court of Canada's new duty of good faith in contracts will apply to IP commercialization

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 17 2014

The Supreme Court of Canada recently reviewed a case involving businesses that marketed education savings plans ("ESP") to investors through retail

Sanofi-Aventis, et al. V. Apotex Inc., et al.

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 10 2014

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis

“Gene Patent” controversy comes to Canada

  • Bereskin & Parr LLP
  • -
  • Canada, USA
  • -
  • November 4 2014

Patents related to isolated DNA corresponding to a gene, as well as methods claiming the diagnostic use of such DNA sequences are often referred to

The Supreme Court of Canada issues new guidance in contractual interpretation

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 3 2014

The Supreme Court of Canada's (SCC) decision in Sattva Capital Corp. v. Creston Moly Corp. established that contractual interpretation will no

3D printing requires 4D thinking on intellectual property

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • October 30 2014

Stories of new uses for 3D printing seem to appear almost daily, as the technology finds its way into everything from cases for mobile phones to

Bill C-43: how the new omnibus budget bill may effect Canadian patent and industrial design law

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • October 24 2014

On October 23, 2014, the Canadian Federal government introduced Bill C-43, an omnibus budget bill also known as the Economic Action Plan 2014 Act, No

Health Canada releases FAQ to new drug name review Guidance document

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • October 23 2014

Earlier this year, Health Canada released the Guidance Document for Industry - Review of Drug Brand Names. With a view to revisiting the 2006 Guidance

F is for fail: the perils of advancing new arguments on appeal of an opposition decision

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • October 17 2014

In an obscenity-laden decision, Justice Mactavish of the Federal Court has confirmed that the Court has discretion to not consider an issue raised

Canada and Europe now connected on the Patent Prosecution Highway

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • October 6 2014

The Canadian Intellectual Property Office ("CIPO") has signed a bilateral agreement with the European Patent Office ("EPO") to establish a Patent

Canada: opening the door to broader trade dress protection

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • October 3 2014

The effects on brand owners of the amendments to the Trademarks Act in Bill C-31 will be wide ranging and varied, but the expanded definition of